Literature DB >> 6142128

Essential hypertension. The behaviour of the haemorheological determinants and their trends during beta-blocker treatment.

G Caimi, A Catania, F Frazzetta, D Capobianco, A Sarno.   

Abstract

We examined the haemorheological determinants in a group of 52 hypertensives (diastolic basal pressure greater than 100 mmHg) subdivided in relation to the clinical stage (I and II or III according to the WHO classification) and in a group of 50 normal controls, matched for age and sex. From this study, it is evident that only plasma viscosity, fibrinogen and the fibrinogen/albumin ratio are able to distinguish normals from hypertensives. It is also clear that the clinical stage does not influence the haemorheological findings. These haemorheological factors were also measured in 3 groups of hypertensives treated with either timolol (20 mg/day), metoprolol (200 mg/day) or oxprenolol (160 mg/day). After a basal evaluation, measurements were performed, at regular intervals of 10 days, for a period of 30 days. The only significant changes were obtained using timolol; metoprolol and oxprenolol, did not affect these haemorheological parameters.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6142128     DOI: 10.1536/ihj.24.723

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  3 in total

1.  The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patients.

Authors:  Bahman Tarighi; Turhan Kurum; Muzaffer Demir; Sen Nur Azcan
Journal:  Can J Cardiol       Date:  2007-06       Impact factor: 5.223

2.  Haemorrheological abnormalities in unstable angina pectoris: a relation independent of risk factor profile and angiographic severity.

Authors:  F J Neumann; H Tillmanns; P Roebruck; R Zimmermann; H M Haupt; W Kübler
Journal:  Br Heart J       Date:  1989-12

3.  Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.

Authors:  R Fogari; A Zoppi; G D Malamani; G Marasi; A Vanasia; G Villa
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.